| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 102 | 2025 | 468 | 14.810 |
Why?
|
| Influenza, Human | 111 | 2025 | 646 | 14.530 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 42 | 2024 | 178 | 7.100 |
Why?
|
| Vaccination | 82 | 2025 | 927 | 5.140 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 48 | 2024 | 118 | 4.230 |
Why?
|
| Seasons | 50 | 2024 | 300 | 3.310 |
Why?
|
| Hospitalization | 55 | 2025 | 1727 | 3.050 |
Why?
|
| Health Personnel | 13 | 2022 | 500 | 2.550 |
Why?
|
| Influenza B virus | 29 | 2024 | 88 | 2.330 |
Why?
|
| Vaccines, Inactivated | 23 | 2024 | 144 | 1.910 |
Why?
|
| United States | 101 | 2025 | 10487 | 1.880 |
Why?
|
| Antibodies, Viral | 17 | 2024 | 1131 | 1.700 |
Why?
|
| Adult | 124 | 2025 | 28733 | 1.660 |
Why?
|
| Emergency Responders | 5 | 2022 | 18 | 1.530 |
Why?
|
| Outpatients | 17 | 2024 | 252 | 1.440 |
Why?
|
| Respiratory Tract Infections | 10 | 2023 | 263 | 1.370 |
Why?
|
| Adolescent | 88 | 2025 | 18940 | 1.320 |
Why?
|
| Influenza A virus | 12 | 2024 | 134 | 1.210 |
Why?
|
| Humans | 197 | 2025 | 122296 | 1.200 |
Why?
|
| Young Adult | 55 | 2025 | 8760 | 1.060 |
Why?
|
| Vaccines, Synthetic | 17 | 2024 | 297 | 1.050 |
Why?
|
| Vaccines, Combined | 12 | 2024 | 38 | 1.040 |
Why?
|
| Middle Aged | 78 | 2025 | 25640 | 1.020 |
Why?
|
| Aged | 72 | 2025 | 18785 | 1.000 |
Why?
|
| Viral Load | 4 | 2023 | 380 | 1.000 |
Why?
|
| Population Surveillance | 14 | 2022 | 381 | 0.980 |
Why?
|
| Case-Control Studies | 27 | 2025 | 3229 | 0.960 |
Why?
|
| Child, Preschool | 59 | 2025 | 13777 | 0.870 |
Why?
|
| Vaccine Potency | 6 | 2020 | 9 | 0.870 |
Why?
|
| Smallpox Vaccine | 1 | 2023 | 36 | 0.840 |
Why?
|
| Prospective Studies | 24 | 2024 | 5963 | 0.830 |
Why?
|
| Ambulatory Care | 11 | 2024 | 376 | 0.820 |
Why?
|
| Male | 90 | 2025 | 59522 | 0.770 |
Why?
|
| Antibody Formation | 5 | 2024 | 255 | 0.760 |
Why?
|
| Female | 93 | 2025 | 64883 | 0.750 |
Why?
|
| Occupations | 1 | 2021 | 21 | 0.750 |
Why?
|
| Hemagglutination Inhibition Tests | 6 | 2024 | 113 | 0.730 |
Why?
|
| Child | 66 | 2024 | 24064 | 0.720 |
Why?
|
| Occupational Diseases | 1 | 2021 | 74 | 0.710 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 176 | 0.700 |
Why?
|
| Infant | 44 | 2025 | 12302 | 0.630 |
Why?
|
| Pneumonia | 1 | 2022 | 325 | 0.620 |
Why?
|
| Immunocompromised Host | 5 | 2024 | 300 | 0.610 |
Why?
|
| RNA, Messenger | 18 | 2024 | 2826 | 0.600 |
Why?
|
| Vaccines, Attenuated | 12 | 2018 | 171 | 0.570 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 105 | 0.520 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 334 | 0.520 |
Why?
|
| Dementia | 1 | 2020 | 441 | 0.510 |
Why?
|
| Social Class | 2 | 2013 | 180 | 0.500 |
Why?
|
| Immunization, Secondary | 5 | 2022 | 105 | 0.500 |
Why?
|
| Emergency Service, Hospital | 12 | 2024 | 1060 | 0.480 |
Why?
|
| Aged, 80 and over | 23 | 2025 | 6291 | 0.450 |
Why?
|
| Cohort Studies | 12 | 2025 | 4643 | 0.430 |
Why?
|
| Pandemics | 5 | 2023 | 1102 | 0.420 |
Why?
|
| Cell Culture Techniques | 3 | 2024 | 288 | 0.420 |
Why?
|
| Asthma | 3 | 2008 | 743 | 0.410 |
Why?
|
| Disease Outbreaks | 4 | 2014 | 318 | 0.380 |
Why?
|
| Hospital Mortality | 7 | 2024 | 996 | 0.380 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 635 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 204 | 0.370 |
Why?
|
| Orthomyxoviridae | 4 | 2014 | 50 | 0.370 |
Why?
|
| Health Status Disparities | 1 | 2013 | 217 | 0.360 |
Why?
|
| Fever | 1 | 2013 | 295 | 0.360 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 93 | 0.310 |
Why?
|
| Critical Illness | 2 | 2023 | 588 | 0.310 |
Why?
|
| Antiviral Agents | 4 | 2022 | 736 | 0.310 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 604 | 0.310 |
Why?
|
| Retropharyngeal Abscess | 2 | 1996 | 7 | 0.260 |
Why?
|
| Administration, Intranasal | 7 | 2010 | 128 | 0.260 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 515 | 0.250 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 453 | 0.250 |
Why?
|
| Patient Acuity | 2 | 2023 | 62 | 0.240 |
Why?
|
| Bias | 1 | 2024 | 113 | 0.230 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 19 | 0.230 |
Why?
|
| Presenteeism | 2 | 2023 | 2 | 0.230 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 10 | 0.220 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 143 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 77 | 0.220 |
Why?
|
| Drug Utilization | 2 | 2015 | 157 | 0.220 |
Why?
|
| Acute Disease | 5 | 2018 | 1090 | 0.220 |
Why?
|
| Fluorocarbons | 1 | 2023 | 57 | 0.210 |
Why?
|
| Self Report | 4 | 2023 | 496 | 0.210 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 68 | 0.210 |
Why?
|
| Treatment Outcome | 13 | 2021 | 12045 | 0.210 |
Why?
|
| RNA, Viral | 5 | 2023 | 540 | 0.200 |
Why?
|
| Computer Simulation | 1 | 2025 | 607 | 0.200 |
Why?
|
| Intention | 1 | 2022 | 94 | 0.200 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 40 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2018 | 1296 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 758 | 0.190 |
Why?
|
| Firefighters | 1 | 2022 | 32 | 0.190 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 17 | 0.190 |
Why?
|
| Age Factors | 8 | 2020 | 2777 | 0.190 |
Why?
|
| Reminder Systems | 1 | 2001 | 60 | 0.190 |
Why?
|
| Carrier State | 1 | 2021 | 76 | 0.190 |
Why?
|
| Vaccination Coverage | 4 | 2023 | 32 | 0.180 |
Why?
|
| Coinfection | 1 | 2022 | 170 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2025 | 384 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2022 | 163 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2023 | 322 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 4 | 0.170 |
Why?
|
| Hospitals | 4 | 2024 | 397 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 2817 | 0.170 |
Why?
|
| Antigenic Variation | 1 | 2020 | 38 | 0.170 |
Why?
|
| Mycobacterium marinum | 1 | 1999 | 1 | 0.170 |
Why?
|
| Oregon | 3 | 2014 | 9 | 0.170 |
Why?
|
| Cheek | 1 | 1999 | 23 | 0.160 |
Why?
|
| Immunity, Herd | 4 | 2024 | 12 | 0.160 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 215 | 0.160 |
Why?
|
| Vaccines | 1 | 2024 | 354 | 0.160 |
Why?
|
| Body Mass Index | 1 | 2024 | 1463 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1999 | 59 | 0.160 |
Why?
|
| Specimen Handling | 2 | 2022 | 137 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 41 | 0.150 |
Why?
|
| Abscess | 1 | 1999 | 138 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 440 | 0.150 |
Why?
|
| Enterococcus faecalis | 1 | 1997 | 43 | 0.150 |
Why?
|
| Antibody Specificity | 2 | 2013 | 204 | 0.150 |
Why?
|
| Immunization Schedule | 3 | 2022 | 102 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 74 | 0.140 |
Why?
|
| Laboratories | 3 | 2021 | 83 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 17 | 0.140 |
Why?
|
| Texas | 6 | 2013 | 3528 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2024 | 822 | 0.140 |
Why?
|
| Office Visits | 2 | 2015 | 75 | 0.140 |
Why?
|
| Washington | 2 | 2013 | 33 | 0.140 |
Why?
|
| Accidents, Home | 1 | 1996 | 9 | 0.140 |
Why?
|
| Foot Injuries | 1 | 1996 | 7 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 594 | 0.130 |
Why?
|
| Mediastinal Emphysema | 1 | 1996 | 11 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 1996 | 17 | 0.130 |
Why?
|
| Medication Errors | 1 | 2018 | 184 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 239 | 0.130 |
Why?
|
| Immunization | 3 | 2023 | 302 | 0.130 |
Why?
|
| Incidence | 5 | 2022 | 3018 | 0.130 |
Why?
|
| Antibodies, Bacterial | 1 | 1997 | 382 | 0.130 |
Why?
|
| Efficiency | 1 | 2015 | 57 | 0.130 |
Why?
|
| Neutrophils | 1 | 1997 | 371 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 3626 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2385 | 0.120 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 68 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 1996 | 201 | 0.110 |
Why?
|
| Asymptomatic Infections | 2 | 2024 | 33 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 1996 | 230 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 333 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1772 | 0.100 |
Why?
|
| Schools | 1 | 2014 | 211 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 244 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 710 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 711 | 0.100 |
Why?
|
| Hepatitis A Antibodies | 1 | 2011 | 9 | 0.100 |
Why?
|
| Hepatitis A Vaccines | 1 | 2011 | 10 | 0.100 |
Why?
|
| Chickenpox Vaccine | 1 | 2011 | 13 | 0.100 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2011 | 13 | 0.100 |
Why?
|
| Time Factors | 4 | 2022 | 6182 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2020 | 1234 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 370 | 0.090 |
Why?
|
| History, 21st Century | 3 | 2017 | 270 | 0.090 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2024 | 58 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 265 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2125 | 0.090 |
Why?
|
| Oxygen | 2 | 2023 | 549 | 0.090 |
Why?
|
| Reference Standards | 2 | 2021 | 240 | 0.080 |
Why?
|
| Risk Factors | 5 | 2024 | 9902 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1462 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1238 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 578 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 454 | 0.080 |
Why?
|
| Nose | 2 | 2020 | 92 | 0.080 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 68 | 0.070 |
Why?
|
| Oropharynx | 2 | 2020 | 33 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 1490 | 0.070 |
Why?
|
| Parents | 2 | 2024 | 1016 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2022 | 1166 | 0.060 |
Why?
|
| Drainage | 2 | 1996 | 254 | 0.060 |
Why?
|
| Propensity Score | 1 | 2025 | 203 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 744 | 0.060 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 145 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 148 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 46 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 26 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 240 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 149 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 218 | 0.050 |
Why?
|
| Police | 1 | 2022 | 8 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 215 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 3307 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 22 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 427 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 25 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 371 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 33 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 238 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 113 | 0.050 |
Why?
|
| Nasopharynx | 2 | 2013 | 80 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 115 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 217 | 0.050 |
Why?
|
| Research Design | 1 | 2025 | 646 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 73 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 475 | 0.050 |
Why?
|
| Sample Size | 1 | 2021 | 79 | 0.050 |
Why?
|
| Absenteeism | 2 | 2014 | 19 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 238 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 279 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 210 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1871 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2010 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1109 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 15853 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 69 | 0.040 |
Why?
|
| Pharyngitis | 1 | 2018 | 31 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 408 | 0.040 |
Why?
|
| School Health Services | 2 | 2010 | 98 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 37 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 364 | 0.040 |
Why?
|
| Blood Bactericidal Activity | 1 | 1997 | 17 | 0.040 |
Why?
|
| Opsonin Proteins | 1 | 1997 | 22 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 189 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 475 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 815 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 176 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1997 | 58 | 0.040 |
Why?
|
| Frailty | 1 | 2019 | 98 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1084 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 487 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2017 | 63 | 0.040 |
Why?
|
| Pharynx | 1 | 2017 | 66 | 0.040 |
Why?
|
| Sinusitis | 1 | 2018 | 117 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1997 | 170 | 0.030 |
Why?
|
| Prevalence | 1 | 2023 | 2371 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 84 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 7092 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1679 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 691 | 0.030 |
Why?
|
| Tibia | 1 | 1996 | 66 | 0.030 |
Why?
|
| Fusarium | 1 | 1996 | 11 | 0.030 |
Why?
|
| Bacillus | 1 | 1996 | 33 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1996 | 90 | 0.030 |
Why?
|
| Health Services | 2 | 2006 | 71 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1997 | 313 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1991 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 657 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1996 | 191 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8096 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 804 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 292 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2083 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2013 | 47 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 65 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 1147 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 394 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1247 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1413 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5013 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 860 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 252 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 61 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 400 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 239 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 373 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2010 | 122 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 252 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2030 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 192 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1568 | 0.020 |
Why?
|
| Family Health | 1 | 2006 | 258 | 0.020 |
Why?
|
| Michigan | 1 | 2005 | 39 | 0.020 |
Why?
|
| Japan | 1 | 2005 | 134 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1367 | 0.010 |
Why?
|